NCT02979613 - Study to Evaluate Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed | Biotech Hunter

Enrollment

490

Participants

Timeline

Start Date

December 29, 2016

Primary Completion Date

September 10, 2018

Study Completion Date

January 30, 2020

Conditions

Chronic Hepatitis B

Interventions

DRUG

TAF

25 mg tablet administered orally once daily

DRUG

TDF

300 mg tablet administered orally once daily

DRUG

TAF Placebo

Tablet administered orally once daily

DRUG

TDF Placebo

Tablet administered orally once daily

Trial Locations (39)

10002

Taipei

10029

New York

11355

Flushing

19107

Philadelphia

20122

Milan

60002

Chiayi City

77478

Sugar Land

Unknown

Los Angeles

Palo Alto

Pasadena

San Diego

San Francisco

San Jose

Baltimore

Boston

Novi

Flushing

New York

Philadelphia

Nashville

Edmonton

Toronto

Vancouver

Hong Kong

Kowloon

Goyang

Seoul

Barcelona

Majadahonda

Kaohsiung City

London

700-721

Daegu

03722

Seoul

03830

Seoul

05505

Seoul

06973

Seoul

135-710

Seoul

152-703

Seoul

E1 1BB

London